-
Something wrong with this record ?
Liver Organoids: Recent Developments, Limitations and Potential
SP. Harrison, SF. Baumgarten, R. Verma, O. Lunov, A. Dejneka, GJ. Sullivan
Language English Country Switzerland
Document type Journal Article, Review
NLK
Directory of Open Access Journals
from 2014
Free Medical Journals
from 2014
PubMed Central
from 2014
Europe PubMed Central
from 2014
Open Access Digital Library
from 2014-01-01
Open Access Digital Library
from 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2014
- Publication type
- Journal Article MeSH
- Review MeSH
Liver cell types derived from induced pluripotent stem cells (iPSCs) share the potential to investigate development, toxicity, as well as genetic and infectious disease in ways currently limited by the availability of primary tissue. With the added advantage of patient specificity, which can play a role in all of these areas. Many iPSC differentiation protocols focus on 3 dimensional (3D) or organotypic differentiation, as these offer the advantage of more closely mimicking in vivo systems including; the formation of tissue like architecture and interactions/crosstalk between different cell types. Ultimately such models have the potential to be used clinically and either with or more aptly, in place of animal models. Along with the development of organotypic and micro-tissue models, there will be a need to co-develop imaging technologies to enable their visualization. A variety of liver models termed "organoids" have been reported in the literature ranging from simple spheres or cysts of a single cell type, usually hepatocytes, to those containing multiple cell types combined during the differentiation process such as hepatic stellate cells, endothelial cells, and mesenchymal cells, often leading to an improved hepatic phenotype. These allow specific functions or readouts to be examined such as drug metabolism, protein secretion or an improved phenotype, but because of their relative simplicity they lack the flexibility and general applicability of ex vivo tissue culture. In the liver field these are more often constructed rather than developed together organotypically as seen in other organoid models such as brain, kidney, lung and intestine. Having access to organotypic liver like surrogates containing multiple cell types with in vivo like interactions/architecture, would provide vastly improved models for disease, toxicity and drug development, combining disciplines such as microfluidic chip technology with organoids and ultimately paving the way to new therapies.
Department of Pediatric Research Oslo University Hospital Oslo Norway
Institute of Immunology Oslo University Hospital Oslo Norway
Institute of Physics of the Czech Academy of Sciences Prague Czechia
Norwegian Center for Stem Cell Research Oslo University Hospital University of Oslo Oslo Norway
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21017823
- 003
- CZ-PrNML
- 005
- 20210729104035.0
- 007
- ta
- 008
- 210726s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fmed.2021.574047 $2 doi
- 035 __
- $a (PubMed)34026769
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Harrison, Sean Philip $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway
- 245 10
- $a Liver Organoids: Recent Developments, Limitations and Potential / $c SP. Harrison, SF. Baumgarten, R. Verma, O. Lunov, A. Dejneka, GJ. Sullivan
- 520 9_
- $a Liver cell types derived from induced pluripotent stem cells (iPSCs) share the potential to investigate development, toxicity, as well as genetic and infectious disease in ways currently limited by the availability of primary tissue. With the added advantage of patient specificity, which can play a role in all of these areas. Many iPSC differentiation protocols focus on 3 dimensional (3D) or organotypic differentiation, as these offer the advantage of more closely mimicking in vivo systems including; the formation of tissue like architecture and interactions/crosstalk between different cell types. Ultimately such models have the potential to be used clinically and either with or more aptly, in place of animal models. Along with the development of organotypic and micro-tissue models, there will be a need to co-develop imaging technologies to enable their visualization. A variety of liver models termed "organoids" have been reported in the literature ranging from simple spheres or cysts of a single cell type, usually hepatocytes, to those containing multiple cell types combined during the differentiation process such as hepatic stellate cells, endothelial cells, and mesenchymal cells, often leading to an improved hepatic phenotype. These allow specific functions or readouts to be examined such as drug metabolism, protein secretion or an improved phenotype, but because of their relative simplicity they lack the flexibility and general applicability of ex vivo tissue culture. In the liver field these are more often constructed rather than developed together organotypically as seen in other organoid models such as brain, kidney, lung and intestine. Having access to organotypic liver like surrogates containing multiple cell types with in vivo like interactions/architecture, would provide vastly improved models for disease, toxicity and drug development, combining disciplines such as microfluidic chip technology with organoids and ultimately paving the way to new therapies.
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Baumgarten, Saphira Felicitas $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Verma, Rajneesh $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway
- 700 1_
- $a Lunov, Oleg $u Institute of Physics of the Czech Academy of Sciences, Prague, Czechia
- 700 1_
- $a Dejneka, Alexandr $u Institute of Physics of the Czech Academy of Sciences, Prague, Czechia
- 700 1_
- $a Sullivan, Gareth John $u Hybrid Technology Hub-Center of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway $u Department of Pediatric Research, Oslo University Hospital, Oslo, Norway $u Norwegian Center for Stem Cell Research, Oslo University Hospital, University of Oslo, Oslo, Norway $u Institute of Immunology, Oslo University Hospital, Oslo, Norway
- 773 0_
- $w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 8, č. - (2021), s. 574047
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34026769 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210726 $b ABA008
- 991 __
- $a 20210729104034 $b ABA008
- 999 __
- $a ind $b bmc $g 1676431 $s 1138265
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 8 $c - $d 574047 $e 20210505 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
- LZP __
- $a Pubmed-20210726